Principal Financial Group Inc. Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Principal Financial Group Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 173,092 shares of the biopharmaceutical company's stock after acquiring an additional 2,828 shares during the period. Principal Financial Group Inc. owned approximately 0.16% of Regeneron Pharmaceuticals worth $181,961,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in REGN. &PARTNERS purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $627,000. Catalina Capital Group LLC increased its holdings in Regeneron Pharmaceuticals by 20.8% in the second quarter. Catalina Capital Group LLC now owns 302 shares of the biopharmaceutical company's stock valued at $317,000 after buying an additional 52 shares in the last quarter. Premier Path Wealth Partners LLC lifted its position in shares of Regeneron Pharmaceuticals by 11.1% during the 2nd quarter. Premier Path Wealth Partners LLC now owns 620 shares of the biopharmaceutical company's stock valued at $651,000 after acquiring an additional 62 shares during the period. Everhart Financial Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 14.8% during the 2nd quarter. Everhart Financial Group Inc. now owns 550 shares of the biopharmaceutical company's stock worth $578,000 after acquiring an additional 71 shares in the last quarter. Finally, Van Lanschot Kempen Investment Management N.V. boosted its stake in shares of Regeneron Pharmaceuticals by 14.5% during the 2nd quarter. Van Lanschot Kempen Investment Management N.V. now owns 7,585 shares of the biopharmaceutical company's stock worth $7,972,000 after acquiring an additional 958 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Down 0.9 %

NASDAQ REGN traded down $6.40 during mid-day trading on Friday, hitting $701.85. The company's stock had a trading volume of 1,889,979 shares, compared to its average volume of 568,354. The firm has a market capitalization of $77.13 billion, a P/E ratio of 17.37, a price-to-earnings-growth ratio of 2.19 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. Regeneron Pharmaceuticals, Inc. has a 52-week low of $693.00 and a 52-week high of $1,211.20. The stock's fifty day simple moving average is $827.27 and its two-hundred day simple moving average is $996.84.

Analyst Ratings Changes

Several brokerages recently issued reports on REGN. Citigroup assumed coverage on Regeneron Pharmaceuticals in a report on Thursday, November 14th. They set a "neutral" rating and a $895.00 price objective for the company. Evercore ISI lowered their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating on the stock in a research note on Thursday, October 24th. BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating for the company in a research note on Friday, November 1st. Bank of America reissued an "underperform" rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Finally, Wolfe Research began coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $1,052.90.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.